$ABUS

Arbutus Biopharma Corp

Runway:9 mo

NasdaqMarket cap: —CIK 0001447028

Upcoming catalysts

0 surfaced

No catalysts surfaced for ABUS yet.

AB-836

Chronic Hepatitis

TKM-080301

Cancer

ARB-001467

Hepatitis B, Chronic

Non-interventional

Long Term Follow-up

AB-101

Chronic Hepatitis b

AB-729

Chronic Hepatitis b

TKM-100201

Ebola Virus Infection

TKM-100802 for Injection

Ebola Virus Infection

Imdusiran

Hepatitis B, Chronic

PRO-040201

Hypercholesterolemia

NCT	Drug	Phase	Status	Primary completion
NCT06277037	Non-interventional	—	Recruiting	2029-08-30
NCT05960240	AB-101	Phase 1	Completed	2025-12-04
NCT04980482	AB-729	Phase 2	Completed	2025-03-13
NCT06245291	Imdusiran	Phase 2	Withdrawn	2024-08-01
NCT04775797	AB-836	Phase 1	Terminated	2022-11-17
NCT02631096	ARB-001467	Phase 2	Completed	2018-05-18
NCT02191878	TKM-080301	Phase 2	Completed	2016-05-01
NCT01262235	TKM-080301	Phase 2	Completed	2015-07-01
NCT02041715	TKM-100802 for Injection	Phase 1	Terminated	2015-07-01
NCT01518881	TKM-100201	Phase 1	Terminated	2012-07-01
NCT00927459	PRO-040201	Phase 1	Terminated	2009-12-01